Albany, NY -- (SBWIRE) -- 09/09/2019 -- Autonomic Dysfunction Market Insights, Epidemiology and Market Forecast-2028
1. Autonomic Disease may be present at any age group; at birth in familial dysautonomia, in teenage years in vasovagal syncope, and between the ages of 30–50 years in familial amyloid polyneuropathy (FAP).
2. Neurodegenerative disorders affecting the autonomic nervous system often occur after the age of 50 years.
3. The prevalence of autonomic dysfunction in Parkinson's disease ranges between 50% and 70%.
DelveInsight launched a new report on Autonomic Dysfunction Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Autonomic Dysfunction market report covers a descriptive overview and comprehensive insight of the Autonomic Dysfunction epidemiology and Autonomic Dysfunction market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Autonomic Dysfunction market report provides insights on the current and emerging therapies.
3. Autonomic Dysfunction market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Autonomic Dysfunction market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Autonomic Dysfunction market.
Request for sample pages
"Autonomic dysfunction is responsible for much of the morbidity associated with frequently encountered neurological disorders, such as Parkinson's disease, multiple sclerosis, cerebrovascular disease, and peripheral neuropathies, as well as with the rarer primary autonomic nervous system degenerations."
The first goal of Autonomic Dysfunction treatment is to manage the disease or condition damaging nerves. Many of the medications used for dysautonomia treatment are considered off-label. The therapeutic agents used in the Autonomic Dysfunction treatment include- Alpha-1 Agonists, Mineralocorticoids, Anticholinergic agents, Beta-adrenergic blocker, Phosphodiesterase inhibitors, Neuromuscular blocker agent, Anticholinergic agent and Corticosteroids. Alpha-1 Agonists are used in orthostatic hypotension if simple measures yield no improvement. Mineralocorticoids agents such as fludrocortisone can be used for orthostatic hypotension treatment. Promotes increased reabsorption of sodium and loss of potassium at renal distal tubules. Anticholinergic agents such as Oxybutynin are useful in cases of difficult bladder emptying. Beta-adrenergic blocker like Metoprolol can be used to treat orthostatic tachycardia in POTS patients. Acetylcholinesterase inhibitor such as Pyridostigmine can be used to treat orthostatic hypotension or orthostatic tachycardia. Phosphodiesterase inhibitors like Sildenafil oral agents act peripherally to induce smooth muscle relaxation of the corpora cavernosa. A selective inhibitor of PDE5 that inactivates cGMP, allowing attenuation of the vasodilatory effect. Neuromuscular blocker agent such as OnabotulinumtoxinA used in patients with hyperhidrosis localized to palmar or axillary region.
There are many therapies which are being used for the management of the Autonomic dysfunction, but they often are ineffective and causes severe adverse effects. As observed, when pharmacological treatments are administered, safety becomes an important concern, and physicians need to bear in mind that many drugs for dysautonomic troubles may treat one symptom while worsening other at the same time (e.g., muscarinic receptor antagonists may cause or aggravate constipation). Clinical trials employing valid outcome measures, targeting specific populations, and of appropriate duration are needed to further evaluate efficacy and safety of drugs for autonomic dysfunction. Moreover, animal models are needed to boost the understanding of the physiopathology of these troubles and to test new drugs. Anticholinergic agent such as Glycopyrrolate used for hyperhidrosis and it acts in smooth muscle, CNS, and secretory glands to blocks action of acetylcholine at parasympathetic sites. Corticosteroids such as Prednisone can be used if an inflammatory cause of the autonomic neuropathy is considered to be autoimmune in nature. Immunosuppressant for treatment of autoimmune disorders; may decrease inflammation by reversing increased capillary permeability and suppressing PMN activity. Stabilizes lysosomal membranes and also suppresses lymphocyte and antibody production.
The launch of the emerging therapies is expected to significantly impact Autonomic Dysfunction treatment scenario in the upcoming years:-
Drugs covered
1. Mesenchymal stem cells
2. TD-9855
3. PTC258
And many others
The key players in Autonomic Dysfunction market are:
1. Celltex Therapeutics
2. Theravance Biopharma
3. PTC Therapeutics
And many others
Table of contents
1. Report Introduction
2. Autonomic Dysfunction Market Overview at a Glance
3. Autonomic Dysfunction Disease Background and Overview
4. Autonomic Dysfunction Epidemiology and Patient Population
5. Autonomic Dysfunction Country- Wise Epidemiology
5.1. United States
5.2. EU-5
5.2.1. Assumptions and Rationale
5.2.2. Germany
5.2.3. France
5.2.4. Italy
5.2.5. Spain
5.2.6. United Kingdom
5.3. Japan
6. Autonomic Dysfunction Treatments & Medical Practices
7. Autonomic Dysfunction Emerging Therapies
7.1. Key Cross Competition
7.2. Mesenchymal stem cells: Celltex Therapeutics
7.3. TD-9855: Theravance Biopharma
8. Autonomic Dysfunction Market Size
8.1. Key Findings
8.2. Total 7MM Autonomic Dysfunction Market Analysis
9. 7MM Autonomic Dysfunction Country-Wise Market Analysis
9.1. United States Market Size
9.2. Germany Market Size
9.3. France Market Size
9.4. United Kingdom Market Size
9.5. Spain Market Size
9.6. Italy Market Size
9.7. Japan Market Size
10. Autonomic Dysfunction Report Methodology
11. DelveInsight Capabilities
12. Disclaimer
13. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight